A commercial-stage mRNA company moving from a COVID-led revenue base towards a broader respiratory and oncology pipeline.
The research case centres on Moderna's transition beyond a single-product COVID franchise. Improved profitability and a higher 2026 outlook are constructive, but the value of the long-term case still depends on commercial launches, pipeline delivery and continued cost discipline.
The chart pack shows the most recent year-on-year revenue change and an illustrative DCF sensitivity across discount-rate and terminal-growth assumptions.
| Metric | Reported evidence | Research read-through |
|---|---|---|
| Revenue | $1.3bn in Q3 2026, up 29% year on year | International COVID vaccine sales and strategic partnerships supported growth. |
| Profitability | $162m GAAP net income, versus a $200m loss in Q3 2025 | Cost control and sales conversion improved the quarter, but seasonality remains relevant. |
| Outlook and cash | 2026 revenue-growth outlook of 15% to 25%; expected year-end cash and investments of $8.1bn to $8.3bn | Liquidity supports the pipeline, while future product diversification remains the key value driver. |
Download the full research note and driver-led model. They are educational portfolio materials, not investment advice.
Sources: Moderna Q3 2026 earnings release. Figures are current as of 11 November 2026.